Does the media favor ATAI or AXSM?

In the previous week, Axsome Therapeutics had 7 more articles in the media than Atai Beckley. MarketBeat recorded 11 mentions for Axsome Therapeutics and 4 mentions for Atai Beckley. Axsome Therapeutics' average media sentiment score of 0.99 beat Atai Beckley's score of 0.75 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RDY or ATAI?

Atai Beckley has a consensus target price of $10.56, suggesting a potential upside of 43.62%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts clearly believe Atai Beckley is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Atai Beckley 1 Sell rating(s) 14 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.06

Does the media refer more to RDY or ATAI?

In the previous week, Atai Beckley had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.98 beat Atai Beckley's score of 0.75 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ATAI or CRNX?

In the previous week, Atai Beckley had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.37 beat Atai Beckley's score of 0.75 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BLTE or ATAI more profitable?

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Belite Bio's return on equity of -11.84% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Atai Beckley -14,938.36% -88.30% -58.88%

Does the media refer more to BLTE or ATAI?

In the previous week, Belite Bio had 14 more articles in the media than Atai Beckley. MarketBeat recorded 18 mentions for Belite Bio and 4 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.75 beat Belite Bio's score of 0.37 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ATAI or LNTH?

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atai Beckley $4.09M 666.46 -$660.05M -$2.18 N/A Lantheus $1.54B 4.24 $233.56M $4.14 24.21

Is ATAI or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Atai Beckley's net margin of -14,938.36%. Lantheus' return on equity of 28.10% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Atai Beckley -14,938.36% -88.30% -58.88% Lantheus 17.69% 28.10% 14.35%

Does the media prefer ATAI or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Atai Beckley. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for Atai Beckley. Lantheus' average media sentiment score of 0.94 beat Atai Beckley's score of 0.75 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Atai Beckley (ATAI) Competitors

$7.35 0.00 (0.00%)

As of 09/11/2026

Compare

ATAI vs. AXSM, RDY, CRNX, BLTE, and LNTH

Should you buy Atai Beckley stock or one of its competitors? Atai Beckley's main competitors and comparable companies include Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), and Lantheus (LNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Atai Beckley compare to Axsome Therapeutics?

Atai Beckley (NASDAQ:ATAI) and Axsome Therapeutics (NASDAQ:AXSM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Axsome Therapeutics has higher revenue and earnings than Atai Beckley. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Axsome Therapeutics	$638.50M	18.11	-$183.17M	-$3.75	N/A

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Atai Beckley has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

Axsome Therapeutics has a net margin of -24.68% compared to Atai Beckley's net margin of -14,938.36%. Atai Beckley's return on equity of -88.30% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Axsome Therapeutics	-24.68%	-265.55%	-28.10%

In the previous week, Axsome Therapeutics had 7 more articles in the media than Atai Beckley. MarketBeat recorded 11 mentions for Axsome Therapeutics and 4 mentions for Atai Beckley. Axsome Therapeutics' average media sentiment score of 0.99 beat Atai Beckley's score of 0.75 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atai Beckley currently has a consensus price target of $10.56, suggesting a potential upside of 43.62%. Axsome Therapeutics has a consensus price target of $267.60, suggesting a potential upside of 21.22%. Given Atai Beckley's higher possible upside, research analysts clearly believe Atai Beckley is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Axsome Therapeutics beats Atai Beckley on 11 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Atai Beckley (NASDAQ:ATAI) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Dr. Reddy's Laboratories has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

In the previous week, Atai Beckley had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.98 beat Atai Beckley's score of 0.75 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Atai Beckley's net margin of -14,938.36%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 19.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dr. Reddy's Laboratories has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.78	$456M	$0.44	27.06
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A

Atai Beckley has a consensus target price of $10.56, suggesting a potential upside of 43.62%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts clearly believe Atai Beckley is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Summary

Dr. Reddy's Laboratories and Atai Beckley tied by winning 8 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Atai Beckley (NASDAQ:ATAI) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Atai Beckley had 1 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.37 beat Atai Beckley's score of 0.75 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Crinetics Pharmaceuticals has a net margin of -1,189.88% compared to Atai Beckley's net margin of -14,938.36%. Crinetics Pharmaceuticals' return on equity of -44.22% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

Crinetics Pharmaceuticals has higher revenue and earnings than Atai Beckley. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Atai Beckley currently has a consensus price target of $10.56, suggesting a potential upside of 43.62%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.65%. Given Atai Beckley's higher possible upside, equities analysts clearly believe Atai Beckley is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market.

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Crinetics Pharmaceuticals beats Atai Beckley on 10 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Atai Beckley (NASDAQ:ATAI) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Belite Bio has higher earnings, but lower revenue than Atai Beckley. Belite Bio is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A

Belite Bio has a beta of -1.23, meaning that its share price is 223% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 19.8% of Atai Beckley shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Belite Bio had 14 more articles in the media than Atai Beckley. MarketBeat recorded 18 mentions for Belite Bio and 4 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 0.75 beat Belite Bio's score of 0.37 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Belite Bio's return on equity of -11.84% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Belite Bio currently has a consensus price target of $218.73, suggesting a potential upside of 25.86%. Atai Beckley has a consensus price target of $10.56, suggesting a potential upside of 43.62%. Given Atai Beckley's higher possible upside, analysts clearly believe Atai Beckley is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Summary

Atai Beckley beats Belite Bio on 9 of the 16 factors compared between the two stocks.

How does Atai Beckley compare to Lantheus?

Atai Beckley (NASDAQ:ATAI) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Lantheus has a net margin of 17.69% compared to Atai Beckley's net margin of -14,938.36%. Lantheus' return on equity of 28.10% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Lantheus	17.69%	28.10%	14.35%

28.4% of Atai Beckley shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 19.8% of Atai Beckley shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Atai Beckley presently has a consensus price target of $10.56, suggesting a potential upside of 43.62%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.84%. Given Atai Beckley's higher probable upside, analysts plainly believe Atai Beckley is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	666.46	-$660.05M	-$2.18	N/A
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.21

In the previous week, Lantheus had 3 more articles in the media than Atai Beckley. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for Atai Beckley. Lantheus' average media sentiment score of 0.94 beat Atai Beckley's score of 0.75 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

Summary

Lantheus beats Atai Beckley on 12 of the 17 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.73B	$12.38B	$7.15B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	-3.37	799.75	274.94	25.36
Price / Sales	666.46	966.93	686.57	116.78
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	10.65	10.39	10.33	6.20
Net Income	-$660.05M	$2.85B	$3.50B	$358.50M
7 Day Performance	-0.54%	-3.61%	-3.32%	-2.35%
1 Month Performance	1.38%	0.72%	-0.53%	-3.23%
1 Year Performance	58.75%	3.61%	23.51%	8.79%

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	2.7574 of 5 stars	$7.35 flat	$10.56 +43.6%	N/A	$2.73B	$4.09M	N/A	80	News Coverage Analyst Upgrade Options Volume
AXSM Axsome Therapeutics	3.7657 of 5 stars	$206.68 flat	$267.60 +29.5%	+86.4%	$10.83B	$638.50M	N/A	380
RDY Dr. Reddy's Laboratories	1.8573 of 5 stars	$11.97 flat	N/A	-18.7%	$9.99B	$3.58B	27.21	27,527
CRNX Crinetics Pharmaceuticals	1.5026 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210	Positive News
BLTE Belite Bio	3.749 of 5 stars	$193.61 flat	$214.64 +10.9%	+150.1%	$7.80B	N/A	N/A	10	Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. AXSM, RDY, CRNX, BLTE, and LNTH

How does Atai Beckley compare to Axsome Therapeutics?

Summary

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Summary

How does Atai Beckley compare to Belite Bio?

Summary

How does Atai Beckley compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. AXSM, RDY, CRNX, BLTE, and LNTH

How does Atai Beckley compare to Axsome Therapeutics?

Which has higher earnings and valuation, ATAI or AXSM?

Do institutionals and insiders hold more shares of ATAI or AXSM?

Which has more risk and volatility, ATAI or AXSM?

Is ATAI or AXSM more profitable?

Does the media favor ATAI or AXSM?

Do analysts rate ATAI or AXSM?

Summary

How does Atai Beckley compare to Dr. Reddy's Laboratories?

Which has more risk & volatility, RDY or ATAI?

Does the media refer more to RDY or ATAI?

Is RDY or ATAI more profitable?

Do institutionals and insiders hold more shares of RDY or ATAI?

Which has preferable earnings & valuation, RDY or ATAI?

Do analysts recommend RDY or ATAI?

Summary

How does Atai Beckley compare to Crinetics Pharmaceuticals?

Does the media prefer ATAI or CRNX?

Is ATAI or CRNX more profitable?

Which has preferable valuation and earnings, ATAI or CRNX?

Do analysts rate ATAI or CRNX?

Which has more risk and volatility, ATAI or CRNX?

Do institutionals and insiders have more ownership in ATAI or CRNX?

Summary

How does Atai Beckley compare to Belite Bio?

Which has higher earnings and valuation, BLTE or ATAI?

Which has more risk and volatility, BLTE or ATAI?

Do insiders and institutionals hold more shares of BLTE or ATAI?

Does the media refer more to BLTE or ATAI?

Is BLTE or ATAI more profitable?

Do analysts recommend BLTE or ATAI?

Summary

How does Atai Beckley compare to Lantheus?

Is ATAI or LNTH more profitable?

Do institutionals and insiders hold more shares of ATAI or LNTH?

Do analysts prefer ATAI or LNTH?

Which has better valuation and earnings, ATAI or LNTH?

Does the media prefer ATAI or LNTH?

Which has more risk and volatility, ATAI or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools